A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
Epistemonikos ID: 673e08066ceeba78a671b83909bc041f64c939b1
First added on: May 21, 2024